← Markets

ProKidney Corp.

PROK · NASDAQ

Market closed$1.62$0.010000 (+0.62%)After hours $1.62 · 0.00%

Key statistics

Previous close$1.61
Open$1.59
Day high$1.66
Day low$1.57
52-week high$3.55
52-week low$1.53
Market cap544.73M
Volume991.35K
Average volume1.10M
P/E ratio-3.06
Forward P/E—
EPS-0.53
Dividend yield0.00%

Market context

Why it moved

PROK edged slightly higher amid modest buying interest, with no significant company-specific news catalysts identified, suggesting the minor uptick reflects general market momentum and light trading activity rather than any major fundamental development.

MashedMarketbeatInstagramAgbullFacebook

What is happening

Recent company-specific developments and publisher coverage.

July 14, 2026ProKidney Corp. tumbled over 8%, closing near its 52-week low of $1.53, as a risk-off day swept through biotech and broader markets on renewed U.S.-Iran military escalation that sent oil prices surging and pressured equities broadly. The XLV healthcare ETF also softened amid Q2 earnings uncertainty, with biotech sector earnings projected to decline sharply. ProKidney, a clinical-stage renal cell therapy company with no approved products, remains highly sensitive to macro sentiment shifts, and the high-volume session—nearly double its average—suggests elevated selling pressure with little company-specific catalyst to arrest the decline. In after-hours trading, shares edged back to $1.65.

-8.5227

July 10, 2026ProKidney Corp. closed down modestly, retreating from its previous close as investors weigh the penny-stock biotech's longer-term prospects for rilparencel, its autologous cellular therapy targeting chronic kidney disease progression. Despite the session dip, the stock is ticking slightly higher in after-hours trading, while the broader healthcare sector — buoyed by analyst commentary calling biotech 'the hottest group in the market' and XLV hitting record highs — provides a constructive backdrop for clinical-stage names like ProKidney even as the company lacks near-term catalysts.

-2.2222

July 10, 2026ProKidney closed down modestly, slipping further in after-hours trading, as investors continue to assess the clinical-stage biotech's prospects amid a broadly bullish backdrop for the healthcare sector. Jim Cramer's recent call labeling biotech "the hottest group in the market" and healthcare's back-to-back sector-leading weeks have done little to lift PROK, which remains a pre-revenue penny stock reliant on its rilparencel cell therapy for chronic kidney disease. A recent Form 4 filing disclosed a 750,000 stock option grant to CTO Kenneth Locke at a $1.89 strike price, while a recent Russell index inclusion has modestly raised the company's institutional visibility.

-2.1739

July 7, 2026ProKidney Corp. closed modestly lower, giving back ground after the session's intraday high of $2.04, as broader market softness weighed on small-cap biotech names. Investor attention remains on the company's clinical-stage cell therapy program for chronic kidney disease, with recent CTO stock option grants at a $1.89 strike signaling management retention investment. The backdrop is constructive for the space: Jim Cramer declared biotech "the hottest group in the market" on July 6, citing a wave of M&A enabled by a more favorable FDA environment, while the healthcare sector ETF (XLV) traded near its 52-week high. ProKidney's recent addition to multiple Russell indices has also boosted visibility, though the pre-revenue company continues to post growing losses.

-2.0101

July 7, 2026ProKidney Corp. declined modestly, underperforming within a broadly mixed healthcare sector as XLV dipped while tech stocks led the broader market higher. Investor attention remains focused on the company's clinical-stage rilparencel therapy for chronic kidney disease, with a recent Simply Wall St feature highlighting its debt-free balance sheet, sufficient cash runway, and newly added Russell index inclusion as positives. Countering that optimism, ProKidney's CTO received a 750,000-share stock option grant, and the company continues to post growing losses with no near-term path to profitability.

-1.9704

July 2, 2026ProKidney Corp. closed down sharply after shares failed to sustain momentum from its recent Russell index additions. On June 29, PROK was added to the Russell 2000, Russell Microcap, Russell Microcap Value Benchmark, and Russell 2500 Growth Benchmark indexes — a development that typically attracts passive fund inflows — yet shares pulled back 7.35% on above-average volume. Analyst consensus carries an average price target of $6.25, implying over 200% upside from current levels, though the stock remains down roughly 24% year-to-date. In after-hours trading, PROK recovered modestly, rising ~3%.

-7.3529

June 30, 2026ProKidney Corp. gained after the company was added to multiple Russell indexes — including the Russell 2000, Russell Microcap Index, and Russell 2000 Value Benchmark — effective with the annual reconstitution. Index inclusions of this nature typically drive forced buying from passive funds tracking these benchmarks, boosting volume well above average. The move comes as the broader healthcare sector (XLV) closed near its 52-week high, outperforming a broader market that was recovering from last week's tech-driven selloff, aided by a U.S.-Iran ceasefire easing Middle East tensions.

3.2787

Stock Titan · June 15, 2026ProKidney (NASDAQ: PROK) legal chief converts paired units to Class A stockInvesting.com · June 2, 2026ProKidney names Kenneth Locke as chief technical officerGlobeNewswire · June 2, 2026ProKidney Appoints Kenneth Locke as Chief Technical OfficerGlobeNewswire · May 15, 2026ProKidney Reports First Quarter 2026 Financial Results and Business HighlightsThe Business Journals · April 10, 2026High stakes: ProKidney pushes toward commercialization as cash dwindles, opportunity awaitsStock Titan · March 25, 2026ProKidney hires ex-Shield CEO Greg Madison for rilparencel launch prepInvesting.com · March 25, 2026ProKidney names Greg Madison as chief commercial officerThe Business Journals · March 20, 2026ProKidney narrows loss to $150M as it eyes crucial kidney treatment trial results
Benzinga · May 15, 2026ProKidney Q1 EPS $(0.14), Inline, Sales $226.000K Beat $143.667K Estimate
Mt Newswire · March 25, 2026ProKidney Names Greg Madison as Chief Commercial Officer
Benzinga · February 2, 2026Prokidney Updates Phase 3 REGEN-006 Trial Enrollment Of ~470 Subjects
Mt Newswire · December 16, 2025HC Wainwright Initiates Coverage on ProKidney With Buy Rating, $12 Price Target
Benzinga · December 3, 202510 Health Care Stocks With Whale Alerts In Today's Session
Benzinga · August 19, 2025Chamath Palihapitiya Returns To SPACs: Past 18 Deals, Investments Average Loss Of 14%

Peers

S&P 500SPX · $7,457.69-1.01%AbCellera Biologics Inc.ABCL · $6.47+4.95%Biohaven Ltd.BHVN · $15.44+8.96%Pharvaris N.V.PHVS · $34.94+3.80%Ocular Therapeutix, Inc.OCUL · $8.97-2.13%Fate Therapeutics, Inc.FATE · $2.78+1.83%Rocket Pharmaceuticals, Inc.RCKT · $3.44+0.88%CRISPR Therapeutics AGCRSP · $47.78-1.63%Editas Medicine, Inc.EDIT · $2.98+3.47%Beam Therapeutics Inc.BEAM · $27.53-3.03%Sana Biotechnology, Inc.SANA · $3.15-0.63%Caribou Biosciences, Inc.CRBU · $1.65-0.60%